Back

Effectiveness of maternal vaccines and long-acting monoclonal antibodies against respiratory syncytial virus hospitalisations in early life: a scoping review of dynamic modelling studies

2025-04-19 public and global health Title + abstract only
View on medRxiv
Show abstract

BackgroundRespiratory syncytial virus (RSV) is a leading cause of respiratory illness and hospitalisation in infants and young children. New pharmaceutical interventions for preventing severe RSV in early life, namely a maternal vaccine and a long-acting monoclonal antibody, have recently been approved and are now available for use. Over the past decade, mathematical models of RSV transmission have been used to predict the impact of novel pharmaceutical interventions, in anticipation of future p...

Predicted journal destinations